Botulinum neurotoxin is both poison and medicine: botulinum therapy and iatrogenic botulism

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Botulinum neurotoxin is the most potent poison known worldwide. Over the past two centuries, its structure and functions have been studied in detail, and obtained in its pure form. Knowledge of the mechanisms of action of botulinum neurotoxin has determined two directions of its possible use: negative, as a biological (toxin) weapon, and positive, as an agent that eliminates pathological muscle hypertonicity and neuropathic pain and can be used for aesthetic purposes (beauty injections).

The lecture presents the chronological development of both directions and provides a detailed analysis of the various uses of botulinum neurotoxin as a medical and cosmetic treatment. Particular attention is paid to the side effects of botulinum therapy and ways to overcome them.

About the authors

Vladimir V. Nikiforov

Pirogov Russian National Research Medical University

Author for correspondence.
Email: v.v.nikiforov@gmail.com
ORCID iD: 0000-0002-2205-9674
SPIN-code: 9044-5289

MD, Dr Sci. (Med.), Professor

Russian Federation, Moscow

References

  1. Bengston IA. Studies on organisms concerned as causative factors in botulism. Hyg Lab Bull. 1924;136:101.
  2. Burke GS. The Occurrence of Bacillus botulinus in Nature. J Bacteriol. 1919;4(5):541–553. doi: 10.1128/jb.4.5.541-553.1919
  3. Kerner J. Neue Beobachtungen über die in Würtemberg so häufig vorfallenden tödtlichen Vergiftungen durch den Genuss geräucherter Würste. Tübingen: Osiander; 1820. 120 S.
  4. Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus: ein Beitrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart: Cotta; 1822. 368 S.
  5. Torrens JK. Clostridium botulinum was named because of association with “sausage poisoning”. BMJ. 1998;316(7125):151. doi: 10.1136/bmj.316.7125.151c
  6. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559–565. doi: 10.1007/s00702-007-0728-2
  7. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19(Suppl. 8):S2–6. doi: 10.1002/mds.20003
  8. Erbguth FJ. Historical note on the therapeutic use of botulinum toxin in neurological disorders. J Neurol Neurosurg Psychiatry. 1996;60(2):151. doi: 10.1136/jnnp.60.2.151
  9. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53(8):1850–1853. doi: 10.1212/wnl.53.8.1850
  10. Erbguth FJ, Naumann M. On the first systematic descriptions of botulism and botulinum toxin by Justinus Kerner (1786–1862). J Hist Neurosci. 2000;9(2):218–220. doi: 10.1076/0964-704X(200008)9:2;1-Y;FT218
  11. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med (Lond). 2004;4(3):258–261. doi: 10.7861/clinmedicine.4-3-258
  12. Keppie J. The pathogenicity of the spores of Clostridium botulinum. J Hyg (Lond). 1951;49(1):36–45. doi: 10.1017/s0022172400015345
  13. Burgasov PN, Rumyantsev SN. The evolution of clostridiosis. Moscow: Meditsina; 1974. 247 p. (In Russ).
  14. Van Heyningen WE. Identity of the tetanus toxin receptor in nervous tissue. Nature. 1958;182(4652):1809. doi: 10.1038/1821809a0
  15. Botulism [internet]. Veterinary service of the Vladimir region. Available from: https://vetvo.ru/botulizm.html Accessed: Feb 14, 2023. (In Russ).
  16. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1-2):10–24. doi: 10.1113/jphysiol.1949.sp004364
  17. Halliwell J, Gwenin C. A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold. Toxins (Basel). 2013;5(8):1381–1391. doi: 10.3390/toxins5081381
  18. Rossow H, Kinnunen PM, Nikkari S. Botulinumtoksiini biouhka-agenssina. Duodecim. 2012;128(16):1678–1684.
  19. Sharma A Botulinum toxin: Bio Warfare Agent and Vaccine Development. Clin Res Trials. 2021;7:1–8. doi: 10.15761/CRT.1000348
  20. Dalin MV, Fish NG. Protein toxins of microbes. Moscow: Meditsina; 1980. 224 p. (In Russ).
  21. Hill EV. Botulism. In: Summary Report on B. W. Investigations. US Library of Congress. 1947; Tab D.
  22. Sotos JG. Botulinum toxin in biowarfare. JAMA. 2001;285(21):2716. doi: 10.1001/jama.285.21.2716
  23. Cochrane RC. History of the Chemical WarfareService in World War II (1 July 1940 — 15 August 1945). In: Biological Warfare Researchin the United States. US Army Medical Research Institute of Infectious Diseases; 1947. Vol. II.
  24. Bryden J. Deadly Allies: Canada’s Secret War, 1937–1947. Toronto, Ontario: McClelland & Stewart; 1989. 314 p.
  25. Lamb A. Biological weapons: the facts not the fiction. Clin Med (Lond). 2001;1(6):502–504. doi: 10.7861/clinmedicine.1-6-502
  26. Ambache N. The peripheral action of Cl. botulinum toxin. J Physiol. 1949;108(2):127–141.
  27. Holzer E. [Botulism caused by inhalation]. Med Klin. 1962;57: 1735–1738. (In German).
  28. Patterns of Global Terrorism 1999. Department of State Publication 10687 [Internet]. Available from: https://1997-2001.state.gov/global/terrorism/1999report/1999index.html Accessed: Feb 14, 2023. (In Russ).
  29. United Nations Security Council. 10th Report of the Executive Chairman of the Special Commission Established by the Secretary-General Pursuant to Paragraph 9(b)(I) of Security Council Resolution 687 (1991), and Paragraph 3 of Resolution 699 (1991) on the Activities of the Special Commission. New York, NY: United Nations Security Council, 1995.
  30. Zilinskas RA. Iraq’s biological weapons. The past as future? JAMA. 1997;278(5):418–424.
  31. Arnon SS, Schechter R, Inglesby TV, et al.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059–1070. doi: 10.1001/jama.285.8.1059. Erratum in: JAMA. 2001;285(16):2081.
  32. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997;40(3):317–327. doi: 10.1353/pbm.1997.0032
  33. Snipe PT, Sommer H. Studies on botulinus toxin. Acid precipitation of botulinus toxin. J Infect Dis. 1928;(43):152–160.
  34. Lamanna C, Eklund HW, McElroy OE. Botulinum toxin (type A); including a study of shaking with chloroform as a step in the isolation procedure. J Bacteriol. 1946;52:1–13. doi: 10.1128/JB.52.1.1-13.1946
  35. Botulinum toxin [Internet]. Wikipedia. Available from: https://ru.wikipedia.org/wiki/Ботулотоксин Accessed: Feb 14, 2023. (In Russ).
  36. Aleksandrov VN, Emelyanov VI. Toxins as a chemical weapon. In: Sokolsky GA, editor. Poisonous substances. 2nd ed. Moscow: Voenizdat; 1990. (In Russ).
  37. Dorsey EL, Beebe JM, Johns EE. Responses of air-borne Clostridium botulinum toxin to certain atmo-spheric stresses. Frederick, Md: US Army Biological Laboratories; 1964. P:62.
  38. Wiener SL. Strategies for the prevention of a successful biological warfare aerosol attack. Mil Med. 1996;161(5):251–256.
  39. Klein AW. Cosmetic therapy with botulinum toxin, Anecdotal memoirs. Dermatol Surg. 1996;22(9):757–759. doi: 10.1111/j.1524-4725.1996.tb00725.x
  40. The history of the discovery of botulinum toxin and its use in medicine [Internet]. Available from: https://meduniver.com/Medical/Dermat/istoria_botulotoksina.html?ysclid=lcgbxuj4dt804707529 Accessed: Feb 14, 2023. (In Russ).
  41. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924–927.
  42. Truong D, Hallett M. Chapter 2. Botulinum neurotoxin: history of clinical development. In: Truong D, Hallett M, Zachary C, Dressler D, editors. Manual of Botulinum Toxin Therapy. 2nd ed. Cambridge University Press, 2013.
  43. Drachman DB. Atrophy of skeletal muscle in chick embryos treated with botulinum toxin. Science. 1964;145(3633):719–721. doi: 10.1126/science.145.3633.719
  44. Soldatov A. How the most dangerous poison became the elixir of youth. The unusual story of Botox. TASS. 2021. Dec 24. Available from: https://nauka.tass.ru/nauka/13286225 Accessed: Feb 14, 2023. (In Russ).
  45. The history of the creation of Botulinum toxin. Pharmedu. 2015. Jan 23. Available from: https://pharmedu.ru/publication/istoriya-sozdaniya-botulotoksin?ysclid=lcgbr3t5vx687455389 Accessed: Feb 14, 2023. (In Russ).
  46. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10): 1044–1049. doi: 10.1016/s0161-6420(80)35127-0
  47. Margolina A. Botulinum toxin in cosmetology — poison or medicine? Science and Life. 2008;(9). Available from: https://www.nkj.ru/archive/articles/14656/?sphrase_id=5329291 Accessed: Feb 14, 2023. (In Russ).
  48. Who Invented Botox [Internet]. Available from: https://md-eksperiment.org/post/20171124-kto-izobryol-botoks Accessed: Feb 14, 2023. (In Russ).
  49. Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):788–797. doi: 10.1016/s0190-9622(96)90016-x
  50. Carruthers A, Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg. 1998;24(11):1168–1170. doi: 10.1111/j.1524-4725.1998.tb04092.x
  51. Carruthers J, Carruthers A. The adjunctive usage of botulinum toxin. Dermatol Surg. 1998;24(11):1244–1247. doi: 10.1111/j.1524-4725.1998.tb04105.x
  52. Carruthers A, Carruthers J. History of cosmetic botulinum toxin. In: Carruthers A, Carruthers J, editors. Botulinum Toxin. New York: Elsevier; 2013. P:16.
  53. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1): 17–21. doi: 10.1111/j.1524-4725.1992.tb03295.x
  54. Carruthers A, Langtry JA, Carruthers J, Robinson G. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache. 1999;39(9):662–665. doi: 10.1046/j.1526-4610.1999.3909662.x
  55. Klein AW, Glogau RG. Botulinum toxin: beyond cosmesis. Arch Dermatol. 2000;136(4):539–541. doi: 10.1001/archderm.136.4.539
  56. Kedlaya D. Botulinum Toxin. Medscape. 2022. Nov 30. Available from: https://emedicine.medscape.com/article/325451-overview Accessed: Feb 14, 2023.
  57. Makagonov GA. Botulinum toxin in medicine and cosmetology. Lecture for doctors. ShopDon. 2022. March 26. Available from: https://shopdon.ru/blog/botulotoksin/ Accessed: Feb 14, 2023. (In Russ).
  58. Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Semin Cutan Med Surg. 2001;20(2):93–100. doi: 10.1053/sder.2001.24423
  59. Gunn RA. Botulism: from van Ermengem to the present. A comment. Rev Infect Dis. 1979;1(4):720–721. doi: 10.1093/clinids/1.4.720
  60. Spencer JM. Botulinum toxin B: the new option in cosmetic injection. J Drugs Dermatol. 2002;1(1):17–22.
  61. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg. 2001;20(2):127–136. doi: 10.1053/sder.2001.24421
  62. Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clin Cosmet Investig Dermatol. 2019;12:223–228. doi: 10.2147/CCID.S202919
  63. Zakin E, Simpson D. Evidence on botulinum toxin in selected disorders. Toxicon. 2018;147:134–140. doi: 10.1016/j.toxicon.2018.01.019
  64. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci. 2000;7(5):389–394. doi: 10.1054/jocn.2000.0684
  65. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129(3): 221–228. doi: 10.7326/0003-4819-129-3-199808010-00011
  66. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(Suppl. 6):S119–124. doi: 10.1097/00002508-200211001-00002
  67. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997;6:S129–145.
  68. Damulin IV. The use of botulinum toxin (dysport) in neurological practice. Neurological Journal. 2000;5(3):39–47. (In Russ).
  69. Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg. 2001;20(2):121–126. doi: 10.1053/sder.2001.25136
  70. Orlova OR. The use of botulinum toxin in neurology and cosmetology. Les Nouvelles Esthetiques (Nouvel Aesthetic). 1998;(7):25–27. (In Russ).
  71. Orlova OR, Timerbaeva SL, Khat’kova SE, et al. Conversion ratio between different botulinum neuroprotein product in neurological practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(9):132–141. (In Russ). doi: 10.17116/jnevro201711791132-141
  72. Preparations of botulinum toxin and their differences [Internet]. Available from: https://meduniver.com/Medical/Dermat/preparati_botulotoksina.html Accessed: Feb 14, 2023. (In Russ).
  73. Khat’kova SE. Xeomin in the treatment of poststroke spasticity. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2010;110(8): 62–64. (In Russ).
  74. Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep. 2012;12(4):399–409. doi: 10.1007/s11910-012-0286-3
  75. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2(8501): 245–247. doi: 10.1016/s0140-6736(86)92070-2
  76. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251(Suppl. 1):I1–7. doi: 10.1007/s00415-004-1102-z
  77. Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 1988;51(7):920–923. doi: 10.1136/jnnp.51.7.920
  78. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(Suppl. 1):S9–15. doi: 10.1046/j.1526-4610.43.7s.3.x
  79. Relja M, Klepac N. Different doses of botulinum toxin A and pain responsiveness in cervical dystonia. Neurology. 2002;58:A474.
  80. Oh HM, Chung ME. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel). 2015;7(8):3127–3154. doi: 10.3390/toxins7083127
  81. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl. 5):21–29. doi: 10.1046/j.1468-1331.2001.00035.x
  82. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26(5): 785–793. doi: 10.1016/j.neuro.2005.01.017
  83. Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm (Vienna). 2008;115(4):567–573. doi: 10.1007/s00702-007-0758-9
  84. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting — a review of the literature. Pain Pract. 2008;8(4):269–276. doi: 10.1111/j.1533-2500.2008.00202.x
  85. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1-2):125–133. doi: 10.1016/j.pain.2003.10.008
  86. Dodick DW, Turkel CC, DeGryse RE, et al.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936. doi: 10.1111/j.1526-4610.2010.01678.x
  87. Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg. 2012;65(10):1283–1291. doi: 10.1016/j.bjps.2012.04.016
  88. Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34(11):853–869. doi: 10.1177/0333102414527648
  89. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–2205. doi: 10.1016/j.pain.2011.06.017
  90. Patil S, Willett O, Thompkins T, et al. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016;20(3):15. doi: 10.1007/s11916-016-0545-0
  91. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–283. doi: 10.1002/ana.21427. Erratum in: Ann Neurol. 2009;65(3):359.
  92. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–1478. doi: 10.1212/01.wnl.0000345968.05959.cf
  93. Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010;11(12):1827–1833. doi: 10.1111/j.1526-4637.2010.01003.x
  94. Godoy IR, Donahue DM, Torriani M. Botulinum Toxin Injections in Musculoskeletal Disorders. Semin Musculoskelet Radiol. 2016;20(5):441–452. doi: 10.1055/s-0036-1594284
  95. Luvisetto S, Gazerani P, Cianchetti C, Pavone F. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. Toxins (Basel). 2015;7(9):3818–3844. doi: 10.3390/toxins7093818
  96. Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017;9(9):260. doi: 10.3390/toxins9090260
  97. Botulinum therapy [Internet]. EMC. Available from: https://www.emcmos.ru/programs_and_services/services/botulinoterapiya/ Accessed: Feb 14, 2023. (In Russ).
  98. Ivanova Yu, Lando E. You know about restrictions when the police approach you: how do women in Turkmenistan live after the ban on Botox, nail extensions and coloring? PEOPLETALK. 2022. July 13. Available from: https://peopletalk.ru/article/ob-ogranicheniyah-uznaesh-kogda-k-tebe-podhodyat-politsejskie-kak-zhivut-zhenshhiny-v-turkmenistane-posle-zapreta-na-botoks-narashhennye-nogti-i-okrashivanie/ Accessed: Feb 14, 2023. (In Russ).
  99. Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon. 2015;107(Pt A):64–67. doi: 10.1016/j.toxicon.2015.07.013
  100. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40(3):374–380. doi: 10.1002/mus.21343
  101. Love SC, Novak I, Kentish M, et al.; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17(Suppl. 2):9–37. doi: 10.1111/j.1468-1331.2010.03126.x
  102. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25. doi: 10.2340/16501977-0303
  103. Authors of works (articles) used in the preparation of materials on botulinum therapy and botulinum toxins [Internet]. Available from: https://meduniver.com/Medical/Dermat/avtori_materialov_statei-2.html Accessed: Feb 14, 2023. (In Russ).
  104. Burke GS. The Occurrence of Bacillus botulinus in Nature. J Bacteriol. 1919;4(5):541–553. doi: 10.1128/jb.4.5.541-553.1919
  105. Vasina V. Botox: How Poison Became a Cosmetic Product and Created a $3 Billion Market. Who Is Behind Rejuvenating Injections. Firm Secret. 2017. Nov 8. Available from: https://secretmag.ru/trends/tendencies/botoks-kak-yad-stal-samym-populyarnym-kosmeticheskim-preparatom-i-sozdal-rynok-na-usd3-mlrd.htm Accessed: Feb 14, 2023. (In Russ).
  106. Cohen JL, Scuderi N. Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review. Aesthet Surg J. 2017;37(Suppl. 1):S32–S44. doi: 10.1093/asj/sjx010
  107. Simidu U. [An introduction to predictive microbiology]. Shokuhin Eiseigaku Zasshi. 2001;42(6):J317–323. (In Japanese).
  108. Botulinum Toxin as a Biological Weapon [Internet]. Available from: https://prezi.com/fzjklsb-bhne/botulinum-toxin-as-a-biological-weapon/?frame=b20d678565cf9cfb68d852d5b6b6175dbac599e8 Accessed: Feb 14, 2023.
  109. Bakheit A. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse; 2007. 216 p.
  110. Margolina AA, Ernandez EI. New cosmetology. Moscow: Firma KLAVEL’; 2007. Vol. 2. 418 p. (In Russ).
  111. Bai L, Peng X, Liu Y, et al. Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT). Medicine (Baltimore). 2018;97(34):e10659. doi: 10.1097/MD.0000000000010659
  112. Ibatullin RA, Magzhanov RV. Case of iatrogenic botulism after botulinotherapy in clinical practice. Terapevticheskii Arkhiv. 2018;90(11):102–104. doi: 10.26442/terarkh20189011102-104
  113. Malov VA, Maleev VV, Pokrovskiy VI. Botulinum toxin therapy and iatrogenic botulism: view of an infectious disease specialist. Infectious Diseases. 2019;17(4):55–61. (In Russ). doi: 10.20953/1729-9225-2019-4-55-61

Copyright (c) 2022 Nikiforov V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies